Johnson & Johnson (NYSE: JNJ) has announced the FDA‘s approval of TREMFYA® (guselkumab) for adults with moderately to severely active ulcerative colitis (UC). This chronic inflammatory condition affects

The U.S. Food and Drug Administration has approved Tremfya (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis. Tremfya is the first and only dual-acting interleukin-23 inhibitor approved in active ulcerative colitis.

Approval of the dual-acting interleukin (IL)-23 inhibitor in ulcerative colitis was based on findings from QUASAR, an ongoing phase IIb/III induction and maintenance program involving patients with inadequate response to conventional drugs, biologics, or a Janus kinase (JAK) inhibitor.

Johnson & Johnson already has a major presence in the crowded inflammatory bowel disease (IBD) space with its popular Stelara. | Tremfya will enter the UC space as J&J’s older Stelara, which is approved to treat both forms of IBD,

Johnson & Johnson has announced that the US FDA has approved TREMFYA for the treatment of active ulcerative colitis (UC).

FDA approves J&J's Tremfya for ulcerative colitis. NVO's oral obesity pill, amycretin, shows faster weight loss than weekly injection, Wegovy.

Johnson & Johnson JNJ announced that the FDA approved its blockbuster immunology medicine, Tremfya (guselkumab), for a third indication. The drug is approved to treat adults with moderately to severely active ulcerative colitis (UC).